MarketBeat cites USD 367.07 average target for Penumbra stock

Published on 10/15/2026 at 21:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Penumbra posted USD 390.05 million revenue in Q2 2026, up 14.90 percent. Penumbra stock costs EUR 286.80 on October 15, 2026 at 9:29 p.m. CEST.

Analyst valuation and trading

MarketBeat reported a USD 367.07 average target on October 9, 2026.
Second-quarter 2026 revenue reached USD 390.05 million, up 14.90 percent year over year.
Penumbra stock costs EUR 286.80 at Lang & Schwarz on October 15, 2026 at 9:29 p.m. CEST.
Nasdaq lists November 4, 2026 as the estimated earnings date.

PEN, US70975L1070, Illustration mit AI erstellt.

MarketBeat reported on October 9, 2026 that analysts assigned Penumbra an average 12-month price target of USD 367.07 and a Hold consensus. Fourteen of 17 analysts rated the stock Hold, while three rated it Buy. The target is 14.19 percent above the USD 321.44 home-exchange price available at the same valuation reference.

Revenue growth remains visible

Penumbra's second-quarter 2026 revenue reached USD 390.05 million, an increase of 14.90 percent from the year-earlier quarter, while diluted earnings per share came to USD 0.88. MarketBeat said the earnings figure was below the USD 1.16 consensus estimate, while revenue exceeded the USD 389.64 million estimate.

Price position and range

The home-exchange quote stood at USD 321.44 on the NYSE on October 15, 2026 at 3:33 p.m. ET, compared with a previous session price of USD 320.12. The 52-week range is USD 221.26 to USD 362.41, placing the latest home-exchange quote 11.32 percent below the high and 45.28 percent above the low. Penumbra's euro quote was EUR 286.80 at Lang & Schwarz on October 15, 2026 at 9:29 p.m. CEST.

Valuation and upcoming date

Penumbra had a market capitalization of USD 12.7 billion and a price-to-earnings ratio of 78.94 on October 15, 2026. Its next earnings announcement is estimated for November 4, 2026, according to Nasdaq. The date is based on historical reporting patterns rather than a company-confirmed calendar entry.

Comparison with peers

Penumbra (NYSE, USD): plus 0.41 percent, P/E 78.94, market capitalization USD 12.7 billion.
Medtronic (NYSE, USD): plus 1.60 percent, P/E 23.53, market capitalization USD 122.5 billion.
Abbott Laboratories (NYSE, USD): plus 2.51 percent, P/E 33.75, market capitalization USD 181.5 billion.

Trading view for investors

The comparison places Penumbra at a higher earnings multiple than the two larger medical-device companies listed above. The target consensus therefore gives valuation more weight than the latest daily movement, while the quarterly revenue increase provides a separate operating measure. The company designs and markets medical devices for neurovascular and peripheral vascular procedures, according to its investor-relations page.

Euro quote after hours

Penumbra's euro quote was EUR 286.80 at Lang & Schwarz on October 15, 2026 at 9:29 p.m. CEST. The NYSE quote was USD 321.44 at 3:33 p.m. ET on the same date, with the two prices shown in their respective trading currencies.

The further course of trading is shown by the continuously updated real-time quote of Penumbra stock.